Susquehanna International Group, LLP Avidity Biosciences, Inc. Call Options Transaction History

Susquehanna International Group, LLP

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$37.21 - $48.14 $2.27 Million - $2.93 Million	-60,900 Reduced 61.64%	37,900 $1.74 Million
Q2 2024 Aug 15, 2024	BUY	$22.73 - $40.85 $422,778 - $759,810	18,600 Added 23.19%	98,800 $4.04 Million
Q1 2024 May 07, 2024	BUY	$9.16 - $25.52 $245,488 - $683,936	26,800 Added 50.19%	80,200 $2.05 Million
Q4 2023 Feb 14, 2024	BUY	$4.87 - $9.37 $129,055 - $248,304	26,500 Added 98.51%	53,400 $483,000
Q3 2023 Nov 14, 2023	BUY	$6.3 - $11.35 $169,470 - $305,315	26,900 New	26,900 $171,000
Q1 2023 May 16, 2023	SELL	$15.35 - $25.65 $572,555 - $956,745	-37,300 Reduced 57.74%	27,300 $419,000
Q4 2022 Feb 14, 2023	SELL	$10.06 - $22.66 $185,104 - $416,944	-18,400 Reduced 22.17%	64,600 $1.43 Million
Q3 2022 Nov 14, 2022	BUY	$15.46 - $23.43 $482,352 - $731,016	31,200 Added 60.23%	83,000 $1.36 Million
Q2 2022 Aug 15, 2022	BUY	$11.18 - $20.5 $141,986 - $260,350	12,700 Added 32.48%	51,800 $753,000
Q1 2022 May 16, 2022	BUY	$14.2 - $23.78 $555,220 - $929,798	39,100 New	39,100 $722,000

256

107M

224K

161K

Ticker RNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,127,000
Market Cap $2.16B
Description
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.